Cargando…
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients
Patients receiving chimeric antigen receptor T cell (CAR-T) therapy may have impaired humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations owing to their underlying hematologic malignancy, prior lines of therapy, and CAR-T-associated hypogammaglobulinemia. C...
Autores principales: | Aleissa, Muneerah M., Little, Jessica S., Davey, Sonya, Saucier, Anna, Zhou, Guohai, Gonzalez-Bocco, Isabel H., Crombie, Jennifer L., Looka, Andrew, Baden, Lindsey R., Issa, Nicolas C., Hammond, Sarah P., Jacobson, Caron A., Sherman, Amy C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995387/ https://www.ncbi.nlm.nih.gov/pubmed/36906276 http://dx.doi.org/10.1016/j.jtct.2023.03.005 |
Ejemplares similares
-
Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
por: Little, Jessica S., et al.
Publicado: (2022) -
1073. SARS-CoV-2 Vaccine-Induced Immunogenicity among Hematopoietic Stem Cell Transplant Recipients (HSCT)
por: Kokogho, Afoke, et al.
Publicado: (2022) -
SARS-CoV-2 Vaccine-Induced Immune Responses Among Hematopoietic Stem Cell Transplant Recipients
por: Kokogho, Afoke, et al.
Publicado: (2023) -
2334. The effectiveness of bivalent COVID-19 booster among patients with hematologic malignancies
por: Aleissa, Muneerah M, et al.
Publicado: (2023) -
733. Letermovir treatment for refractory or resistant cytomegalovirus infection or disease with concurrent organ dysfunction: an interim analysis of a Phase 2 open label study.
por: Gonzalez-Bocco, Isabel H, et al.
Publicado: (2022)